Landiolol hydrochloride - Ono Pharmaceutical

Drug Profile

Landiolol hydrochloride - Ono Pharmaceutical

Alternative Names: Corebeta; Low-dose landiolol; ONO-1101; Onoact; Onoact 50

Latest Information Update: 02 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ono Pharmaceutical
  • Class Antiarrhythmics; Morpholines; Small molecules; Urea compounds
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ventricular fibrillation; Arrhythmias; Ventricular tachycardia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Arrhythmias; Coronary disorders; Supraventricular tachycardia
  • Preregistration Ventricular arrhythmias
  • Phase II/III Atrial fibrillation; Atrial flutter

Most Recent Events

  • 30 Jul 2018 Preregistration for Ventricular arrhythmias in Japan (IV)
  • 10 Nov 2017 Ono pharmaceutical plans the J-Land 3S phase II/III study for Tachycardia in Japan (JapicCTI-173767)
  • 31 Aug 2016 Landiolol hydrochloride - Ono Pharmaceutical receives Orphan Drug status for Arrhythmia, Ventricular tachycardia and Ventricular fibrillation in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top